Q4 2024 marked the conclusion of a turnaround year for life sciences venture investment. After two consecutive years of declining activity and macroeconomic uncertainty, the dust has settled, and investment is back on the...more
Since the previous quarter’s Life Sciences Snapshot, robust dealmaking activity in Q3 has launched YTD life sciences VC deal activity to near parity with 2023 figures, firmly positioning 2024 as the year to break the two-year...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2024 include: • Life sciences VC deal value reached $10.6 billion in Q2 2024, up more than 30% from Q1, which brings the...more
Earnout provisions are common in life sciences and healthtech mergers and acquisitions, particularly when an acquired company may add significant value after closing. This can occur if the acquired business has a product in...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2024 include: • Life sciences VC deal value in Q1 totaled $7.8 billion, which represents a 22.1% increase in value from Q4...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2023 include: • Life sciences VC deal value in Q4 2023 totaled $6.6 billion, representing a 25.0% decrease from the prior...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include:
Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2023 include:
• Life sciences VC deal value in Q2 2023 totaled $6.7 billion across 384 deals, representing a slight...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include:
• Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2022 include:
• The industry generated $6.2 billion in deal value across 352 deals in Q3, exhibiting further quarterly...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2022 include:
• The industry generated $8.8 billion in deal value across 362 deals in Q2, a material decline from Q1, as...more
This edition of Orrick’s life sciences publication series breaks down the key drivers of venture investment in the life sciences industry during Q1 2022, which saw some disruptions following a record year in 2021.
Key...more
This edition of Orrick’s life sciences publication series reviews the key drivers of venture investment in the life sciences industry, which is proceeding at a record pace thus far in 2021. Key findings include:
Investment...more